Session: SAT 270-310-Thyroid Neoplasia (posters)
Poster Board SAT 298
Methods: A retrospective study that assessed patients with DTC undergoing RIT after TT. The sTg levels after TT and before RIT were correlated with the ongoing risk stratification 1 year after RIT. Nonparametric Kruskal-Wallis and Mann-Whitney tests were used. ROC curve analysis was performed in order to find a cutoff level of sTg before RIT that can be considered a good predictor of response to initial treatment.
Results: Fifty six patients have been enrolled (mean age 44.7±14.4 years), most of them had papillary carcinoma (80.7%). Regarding the TNM staging 51.8% was classified as stage I, 3.6% stage II, 28.6% stage III and 16.1% stage IV while according the ATA staging 14.3% was at a low risk, 69.6% intermediate risk and 16.1% high risk of recurrence. The mean Tg levels before RIT was 6.4±13.8 ng/ml. Most patients (67.3%) had an excellent response after 1 year of treatment while 15.4% had an acceptable and 17.3% had an incomplete response. Patients with ER had a mean Tg=2.1±3.3 ng/ml, those with AR had a mean Tg=8.2±9.2 ng/mL and patients with IR had a mean Tg=22.4±28.3 ng/mL. We found a statistical significance difference among the 3 ongoing risk stratification groups regarding the Tg levels before RIT (p=0.01). This difference was observed comparing the groups ER vs. IR (p=0.009), but not ER vs. AR and IR vs. AR. The ROC curve analysis showed an area under the curve of 0.779 assuming a Tg value of 3 ng/ml.
Conclusion: We found a correlation between sTg before RIT and the ongoing risk stratification proposed by ATA. It is suggested that the higher the Tg, the greater the likelihood of an incomplete response to the initial treatment. In the literature, the Tg cutoff greater than 10 ng / ml is a major predictor of a negative response to treatment, despite having a higher specificity and reduced sensitivity. In this study, we found that a 3 ng/ml cutoff has higher sensitivity and acceptable specificity (85%) and can be a good predictor of response to initial treatment in patients with DTC.
Nothing to Disclose: LB, ALTT, ANC, NMS, MMM, RDPP, CF
*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo
See more of: Abstracts - Orals, Poster Previews, and Posters